Filter Results:
(247)
Show Results For
- All HBS Web
(247)
- News (56)
- Research (171)
- Events (3)
- Multimedia (3)
- Faculty Publications (59)
Show Results For
- All HBS Web
(247)
- News (56)
- Research (171)
- Events (3)
- Multimedia (3)
- Faculty Publications (59)
- 27 Jun 2005
- Research & Ideas
The Potential Downside of Win-Win
pharmaceutical firm B creates a drug that treats the same ailment and prepares to bring the drug to market. According to best estimates, this new competition will reduce the View Details
Keywords: by Max H. Bazerman
- 06 Oct 2020
- Blog Post
2+2 Where Are They Now Spotlight: Curtis Wu (MBA 2018)
Can you describe your role?I currently work at Amgen Inc at their global HQ in Southern California. Amgen is the largest independent biotechnology company in the world by revenue and our top medicines include autoimmune drug Enbrel, white... View Details
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- 01 Dec 2013
- News
Your Own Medicine
relatively low price of $1.1 million, develop it specifically for DMD, and let the VC investors reap the rewards when and if the drug was successfully commercialized. To make that happen, Williams said, the... View Details
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
price increases and transparency about prices. He initiated a 32 percent price reduction on one of Merck’s most promising new drugs for Hepatitis C, Zepatier. In addition, he... View Details
Keywords: by Bill George
- 04 Sep 2019
- News
Accelerating Scientific Discovery
related to the market. He says that the case studies he and his fellow instructors have written will encourage discussions about topics such as the ways companies determine the pricing of a novel drug to... View Details
Keywords: Jennifer Gillespie
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
drug business. They relied, however, on licensing rather than building their own in-house capabilities for drug discovery and commercialization. In the low-tech OTC [over-the-counter] sector, they... View Details
- Web
Suppliers - Institute For Strategy And Competitiveness
they will benefit from healthy and sustainable competition. Several leading suppliers are refocusing their efforts to achieve value when they introduce new products and drugs. The move to paying for value will mean that the pricing... View Details
- 27 Feb 2020
- Sharpening Your Skills
How Following Best Business Practices Can Improve Health Care
care, but there is another cost to be accounted for. Germany May Have the Answer for Reducing Drug PricesIn Germany, drugmakers must prove that a new medication’s benefits merit a higher price than existing... View Details
- Web
Propose an Independent Project | MBA
Bank/Broker-dealer back-office segment Helping the CEO determine how to manage the business and political issues around the pricing and marketing of prescription drugs Analyzing the appropriateness of an... View Details
- 01 Sep 2008
- News
In Africa, Porter Sees Lessons for Health Care
delivery systems of both developing and advanced countries: fragmentation, inefficiency, and organization around discrete interventions (such as delivering drugs or screening) rather than integrated care. Porter and his colleagues aim to... View Details
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
South Africa over its attempt to reduce the cost of HIV drugs through parallel importation (buying pharmaceuticals in countries with lower prices and then importing them) and compulsory licensing (requiring... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman
- 01 Aug 2017
- First Look
First Look at New Research and Ideas, August 1
drugs (chemically-synthesized, “small-molecule” drugs) face price competition from generic drugs after patent expiration, biosimilars—biologic View Details
Keywords: Sean Silverthorne
- 23 Apr 2014
- HBS Case
Are Electronic Cigarettes a Public Good or Health Hazard?
Drug Administration is proposing the first federal oversight of the product. The very fact users could control the amount of nicotine they ingested led to worry that e-cigarettes would cause smokers to take in more nicotine, rather than... View Details
- 19 Nov 2014
- HBS Case
Marketing Marijuana
something that hadn't been done in 81 years—make an illegal drug legal. “They do not need to buy it at a fancy store—they'll go to a back alley basement shop as long as the product delivers” Of course, the question remains: How will state... View Details
- 12 Feb 2019
- First Look
New Research and Ideas, February 12, 2019
Devices: Challenges and Opportunities for U.S. Regulators and Innovators By: Gordon, William J., and Ariel Dora Stern Abstract— Software has become an increasingly important component of medical device technology. Through legislation like the 21st Century Cures Act as... View Details
Keywords: Dina Gerdeman
- 01 Jun 2010
- News
$how Me the Money
Bank made a $160 million settlement with the Justice Department, agreeing it had been lax about accepting drug money from Mexico.) While U.S. law is tough on drug trafficking, terrorist financing, bank... View Details
- 03 Mar 2009
- First Look
First Look: March 3, 2009
crucially so—on whether or not the platforms subsidize one side of the market in equilibrium. For example, with prices being strategic complements across platforms, we show that a cost-reducing investment by one firm may have a positive... View Details
Keywords: Martha Lagace
- 13 Jul 2009
- Research & Ideas
Diagnosing the Public Health Care Alternative
multiplied by a marginal Federal borrowing cost of 3 percent), eliminating any price advantage of Medicare. The comparison between the administrative expenses of private insurers and Medicare also ignores the fact that Medicare pays no... View Details
- 16 Oct 2013
- Op-Ed
Response to Readers: Combating Climate Change with Nuclear Power and Fracking
With more than 7,500 views and 180-plus tweets, I want to thank everyone for taking the time to read the original HBS Working Knowledge piece, The Case for Combating Climate Change with Nuclear Power and Fracking, and, in particular, for sharing your thoughts with one... View Details